BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 4083212)

  • 21. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Individualized therapy with alpha-interferon in metastatic renal cell carcinoma].
    Gross AJ; Dieckmann KP; Krain J; Huland H
    Urologe A; 1995 Mar; 34(2):158-61. PubMed ID: 7754588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The therapy of renal cell carcinoma with human lymphoblastoid interferon].
    Masuda F; Suzuki M; Ikemoto I; Yamazaki H; Machida T
    Hinyokika Kiyo; 1984 May; 30(5):615-9. PubMed ID: 6206703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Interferon alpha and gamma in the treatment of renal cell carcinoma].
    Kawai K; Sato K; Nishijima Y; Sasaki A; Yamashita J; Ishikawa H; Koiso K
    Nihon Jinzo Gakkai Shi; 1990 Feb; 32(2):231-6. PubMed ID: 2112656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma.
    Tatsugami K; Eto M; Harano M; Hamaguchi M; Miyamoto T; Morisaki T; Furue M; Akashi K; Naito S
    Int J Urol; 2008 Aug; 15(8):694-8. PubMed ID: 18564205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
    Rinehart JJ; Malspeis L; Young D; Neidhart JA
    J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon in metastatic renal cell carcinoma.
    Fosså SD
    Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase II study of recombinant human interferon gamma (S-6810) in renal cell carcinoma. Urological Cooperative Study Group of Recombinant Human Interferon Gamma (S-6810)].
    Machida T; Koiso K; Takaku F; Ogawa M
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):440-5. PubMed ID: 3101607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
    Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
    Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunological assessment after radical nephrectomy for renal cell carcinomas pre-treated with interferon-gamma].
    Onishi T; Machida T; Masuda F; Igarashi H
    Hinyokika Kiyo; 1991 Jul; 37(7):671-8. PubMed ID: 1927765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal cell carcinoma: treatment with interferon.
    Grosh WW
    Compr Ther; 1987 Jun; 13(6):34-9. PubMed ID: 2438082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of pulmonary metastasis from renal cell carcinoma in which complete remission was achieved by interferon therapy (r-IFN-alpha A, Ro 22-8181)].
    Ishito N; Wada F; Aramaki K; Asano S; Johsen T
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):380-3. PubMed ID: 3947113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
    Vugrin D; Hood L; Laszlo J
    J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
    Noguchi S; Shuin T; Kubota Y; Masuda M; Yao M; Hosaka M
    Hinyokika Kiyo; 1995 Jul; 41(7):517-20. PubMed ID: 7668181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sequential combination therapy with alpha interferon and OK-432 (streptococcal preparation) against advanced renal cell carcinoma].
    Marumo K; Mura M; Deguchi N; Baba S; Jitsukawa S; Nakazono M; Tazaki H
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2434-9. PubMed ID: 3729498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.